KyungDong Pharm home
Prescription Medicines

Pitrovan Tab. 2mg

Product Category
Dyslipidemia treatment
Active Ingredients
Pitavastatin Calcium Hydrate
Appearance
Light pink, round, film-coated tablets
Reimbursement Code
648104380
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Pitavastatin calcium hydrate (JP) --- 2.2mg (2mg as pitavastatin calcium)
- Additives (tar color aluminum lake): Red No. 40, Blue No. 2, Yellow No. 5
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Magnesium metasilicate aluminate, magnesium stearate, Opadry pink (03B640005), low-substituted hydroxypropyl cellulose, hypromellose

2. Effectiveness
Dietary supplement to reduce elevated total cholesterol, LDL-cholesterol, apo-B protein and triglyceride levels and increase HDL-cholesterol in patients with primary hypercholesterolemia (heterozygous familial and non-familial, Fredrickson type lla) and mixed dyslipidemia (Fredrickson type llb)

3. Dosage and dosage
Patients before and while taking this drug must follow a standard cholesterol-lowering diet. For adults, the initial dose is usually 1 to 2 milligrams of pitavastatin calcium once a day. If the effect of lowering LDL-cholesterol levels is not sufficient, the dose can be increased up to 4 milligrams per day. Depending on the LDL-cholesterol level, treatment goals, and patient response, the dose is appropriately increased or decreased at intervals of 4 weeks or more, and the therapeutic effect of this drug is maintained with continuous administration.

4. Precautions for use
1. Do not administer to the following patients:
(1) Patients with a history of hypersensitivity to the components of this drug
(2) Patients with active liver disease or persistent elevation of transaminase levels for unknown cause
(3) Patients with severe hepatic impairment or biliary obstruction and patients with cholestasis
(4) Patients taking cyclosporine
(5) Patients with myopathy
(6) Pregnant or pregnant women and lactating women
(7) Children (no experience in use)
(8) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients:
(1) For patients with confirmed abnormalities in clinical tests related to renal function, caution should be exercised as rhabdomyolysis and accompanying rapid deterioration of renal function may occur when co-administered with fibrate-based drugs (e.g. gemfibrozil, bezafibrate, etc.) or nicotinic acid, and it is especially advisable to avoid co-administration with fibrate-based drugs.
(2) Patients with hepatic impairment or a history of it (This drug is mainly metabolized and acts in the liver, so it may worsen hepatic impairment.)
(3) Patients with excessive alcohol intake
(4) Patients with renal impairment or a history of it (Like other HMG-CoA reductase inhibitors, the incidence of rhabdomyolysis may be high in patients with renal impairment, and rapid deterioration of renal function may occur due to rhabdomyolysis.)
(5) Patients taking fibrate-based drugs (e.g. gemfibrozil, bezafibrate, etc.) and nicotinic acid (prone to rhabdomyolysis)
(6) Patients with hypothyroidism, patients with genetic muscle disease or family history thereof, patients with a history of muscle dysfunction caused by drugs
(7) Elderly people
(8) This drug contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
(9) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported).

3. Adverse reactions
In clinical trials, adverse reactions occurred in 197 out of 886 cases (22.2%). There were 50 cases (5.6%) of subjective subjective symptoms, and the main symptoms were abdominal pain, rash, malaise, paralysis, and itching. There were 167 cases (18.8%) of adverse reactions related to clinical test values, the main ones being increased γ-GT, increased plasma creatine phosphokinase (CPK) level, increased serum ALT (GPT), and increased serum AST (GOT) (when approved in Japan). According to the use results survey in Japan, adverse reactions were recognized in 1,210 cases (6.0%) out of 20,002 cases subject to safety reports.
As a result of domestic clinical trials, one additional case of increased total protein was reported.
(1) Rhabdomyolysis (frequency unknown): Rhabdomyolysis is characterized by muscle pain, weakness, elevated CPK levels, and elevated myoglobin in the blood and urine. Severe renal impairment such as acute renal failure may occur accompanying this. If these symptoms appear, administration should be discontinued. There have been rare reports of deaths due to rhabdomyolysis following the use of statin drugs, including this drug.
(2) Myopathy (unknown frequency): Myopathy may occur, so administration should be discontinued if widespread muscle pain, muscle tenderness, or a significant increase in CPK levels occurs.
(3) Liver dysfunction, jaundice (less than 0.1%): Liver dysfunction and jaundice accompanied by significant elevations of AST (GOT) and ALT (GPT) may occur. Therefore, sufficient observations such as regular liver function tests should be performed. If abnormalities are confirmed, administration of this drug should be discontinued and appropriate measures should be taken.
(4) Decrease in platelets (frequency unknown): Decrease in platelets may occur, so sufficient observation such as blood tests should be conducted, and if abnormalities are confirmed, administration should be stopped and appropriate measures should be taken.
(5) Hypersensitivity: In rare cases, urticaria may appear, and occasionally symptoms such as rash and itching may occur, and urticaria, erythema, and angioedema may occur. If these symptoms appear, administration should be discontinued.
(6) Liver: Rarely, an increase in bilirubin and cholinesterase may occur, and sometimes an increase in AST (GOT), an increase in ALT (GPT), an increase in γ-GT, an increase in ALP, and an increase in LDH may occur. Therefore, sufficient observation should be conducted and administration should be discontinued if these symptoms appear.
(7) Mental nervous system: Rarely, stiffness, drowsiness, and insomnia may occur, and sometimes headaches, heaviness, stiffness, paralysis, and dizziness may appear.
(8) Digestive system: In rare cases, dry mouth, indigestion, abdominal pain, abdominal bloating, constipation, stomatitis, vomiting, loss of appetite, and glossitis may occur, and sometimes nausea, stomach discomfort, and diarrhea may occur.
(9) Blood system: Rarely, thrombocytopenia, granulocytosis, leukocytosis, eosinophilia, leukocytosis, globulin elevation, and Coombs test positivity occur, and sometimes anemia may occur.
(10) Kidney: In rare cases, frequent urination, elevated BUN, and elevated serum creatinine may occur.
(11) Endocrine system: Rarely, a decrease in aldosterone, an increase in aldosterone, an increase in ACTH, and an increase in cortisol occur, and occasionally a decrease in testosterone may occur.
(12) Muscle: Rarely, muscle cramps occur, and sometimes CPK elevation, muscle pain, and weakness may occur.
(13) Others: In rare cases, palpitations, fatigue, skin pain, burning sensation, joint pain, edema, blurred vision, flash vision, hearing loss, urinary occult blood, increased uric acid levels, increased serum potassium and phosphorus levels, and dysgeusia may occur. Occasionally, malaise and positive antinuclear antibodies may occur.
ㆍThe following adverse reactions have been reported in relation to some statin drugs.
- Neuropsychiatric system: sleep disorders (including insomnia and nightmares), memory loss, depression
- Respiratory system: exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction
- Endocrine system: diabetes; The frequency varies depending on the presence of risk factors.
(Fasting blood sugar 5.6 to 6.9 mmol/L, BMI>30kg/m2, increased triglyceride level, high blood pressure)
- Musculoskeletal and connective tissue disorders: Immune-mediated necrotizing myopathy
- The induction or worsening of severe muscle atony or ocular muscle atony has been reported in connection with the administration of statin drugs.
ㆍDomestic post-marketing survey results
As a result of a usage outcome survey conducted on 5,659 patients over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 4.14% (234/5,659, 315 cases) regardless of causal relationship.
① The occurrence rate of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 2.19% (124 people/5,659 people, 171 cases), ALT increase 0.76% (43 people/5,659 people, 43 cases), hypochromic anemia 0.44% (25 people/5,659 people, 25 cases), and AST increase. The following was reported: 0.42% (24 people/5,659 people, 24 cases), CPK increase 0.16% (9 people/5,659 people, 9 cases), and muscle pain 0.12% (7 people/5,659 people, 7 cases). Other reported adverse drug reactions are classified by body organ as follows.
- Whole body: facial edema, edema, arm edema, hypersensitivity
- Nervous system: Headache, dizziness, numbness of the skin
- Mental system: insomnia, sleeping disorders, loss of appetite
- Circulatory system: Increased blood pressure, chest discomfort
- Musculoskeletal system: Asthenia
- Gastrointestinal system: abdominal pain, indigestion, dry mouth, constipation, nausea
- Hepatobiliary system: increased γ-GT
- Metabolism and nutrition: increased LDH, increased ALP
- Skin and appendages: itching, hives
- Blood: Thrombocytopenia
- Urinary tract: Increased blood creatinine, increased BUN
② The occurrence rate of unexpected adverse events was 0.74% (42 people/5,659 people, 46 cases), and among these, adverse drug reactions for which a causal relationship with this drug could not be ruled out were increased blood pressure at 0.07% (4 people/5,659 people, 4 cases), skin numbness and chest discomfort at 0.02% each (1 person/5,659 people, 1 case).
③ The incidence of adverse events in patients with renal impairment was 14.01% (44/314, 62 cases), showing a statistically significant difference. Among these, adverse drug reactions for which a causal relationship with this drug could not be ruled out were 10.83% (34 people/314 people, 45 cases), and hypochromic anemia was observed at a high rate of 6.37% (20 people/314 people, 20 cases).
④ In spontaneous reports reported during the post-marketing surveillance period, rhabdomyolysis was reported in one patient.

4. General precautions
(1) Since this drug is effective for hyperlipidemia, the main symptom of which is hypercholesterolemia, administration should be considered after conducting sufficient tests to confirm hypercholesterolemia before administration.
(2) Before administration, diet should be implemented in advance, and exercise therapy and reduction of risk factors for ischemic heart disease such as high blood pressure and smoking should also be considered.
(3) Blood lipid levels should be checked regularly during administration, and administration should be discontinued if no response to treatment is recognized.
(4) When administering to patients with hepatic impairment, the starting dose is 1 mg per day and the maximum dose is 2 mg per day.
(5) As the dose of this drug may increase, adverse reactions related to rhabdomyolysis may occur, so when increasing the dose up to 4 mg, caution should be taken for prodromal symptoms of rhabdomyolysis such as elevated CK, myoglobinuria, myopathy, and weakness.
(6) Because aminotransferase levels may increase, liver function tests should be performed before and during administration. Liver function tests are performed at least once within 12 weeks from the start of administration, and regularly thereafter (once every 6 months, etc.). Particular caution should be exercised in patients with elevated serum transaminase levels, and liver function tests should be performed promptly and frequently.
(7) Skeletal muscle: There have been reports that the administration of other HMG-CoA reductase inhibitors is rarely associated with causing myositis, so it is advisable to discontinue administration if there are clinical signs of myositis or an increase in CPK level.
(8) This drug has not been studied for Fredrickson types Ⅰ, Ⅲ, Ⅳ, and Ⅴ.
(9) There has been no study on homozygous familial hypercholesterolemia due to functional LDL receptor deficiency.
(10) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, non-productive coughing and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
(11) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6 to 6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to clinical practice guidelines.
(12) Immune-mediated necrotizing myopathy: Immune-mediated necrotizing myopathy, an autoimmune myopathy related to statin use, has been reported. Immune-mediated necrotizing myopathy manifests as proximal muscle weakness and increases in blood CPK, and the symptoms persist even after discontinuation of statin administration. Additionally, muscle biopsy shows necrotizing myopathy without significant infection, and symptoms improve upon administration of immunosuppressants.
(13) In rare cases, statin drugs may cause or worsen severe muscle atony or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.

5. Interaction
This drug is poorly metabolized by CYP450. (Slightly metabolized by CYP2C9.)
(1) Cyclosporine increases the blood concentration of this drug (Cmax 6.6 times, AUC 4.6 times) and serious adverse reactions such as rhabdomyolysis accompanied by rapid deterioration of renal function are likely to occur, so it should not be administered in combination with cyclosporine.
(2) In patients with abnormal clinical test values for renal function, it is advisable to avoid coadministration because rhabdomyolysis accompanied by rapid deterioration of renal function is likely to occur when coadministered with fibrate-based drugs (e.g., bezafibrate, etc.). If it is judged to be unavoidable for treatment and co-administration shows deterioration of renal function such as the appearance of subjective symptoms (muscle pain, weakness), increased CPK level, increased myoglobin in blood and urine, and increased serum creatinine, administration should be discontinued immediately.
(3) When co-administered with fibrate-based drugs (e.g., gemfibrozil, bezafibrate, etc.), rhabdomyolysis accompanied by rapid deterioration of renal function has been reported regardless of the presence or absence of renal impairment, so caution should be exercised during co-administration, and worsening of renal function such as appearance of subjective symptoms (muscle pain, weakness), increased CPK level, increased myoglobin in blood and urine, and increased serum creatinine may occur. If this occurs, administration should be stopped immediately.
(4) When used in combination with nicotinic acid, if there is renal impairment, rhabdomyolysis accompanied by rapid deterioration of renal function is likely to occur, so caution should be exercised during co-administration. In case of deterioration of renal function, such as the appearance of subjective symptoms (muscle pain, weakness), increased CPK level, increased myoglobin in blood and urine, and increased serum creatinine, administration should be stopped immediately.
(5) Because the absorption of this drug may be inhibited by combined use with cholestyramine and the blood concentration may decrease, it is advisable to administer this drug at a sufficient interval after administration of cholestyramine.
(6) When administered in combination with erythromycin, rhabdomyolysis accompanied by rapid deterioration of renal function may occur. If renal function deteriorates, such as subjective symptoms (muscle pain, weakness), increased CPK, increased blood and urine myoglobin, or increased serum creatinine, administration should be discontinued immediately.
(7) There is a report that the Cmax of this drug increased by 2.0 times and the AUC by 1.3 times when used in combination with rifampicin.
(8) Interaction studies between pitavastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when statins and fusidic acid were used together in post-marketing experience. Therefore, combined use of pitavastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue pitavastatin administration, and if administration is unavoidable, close monitoring should be performed.

6. Administration to elderly people
Since physiological functions are generally reduced in elderly people, caution should be exercised, such as reducing the dose if adverse reactions occur. (There are reports that rhabdomyolysis is likely to occur.)

7. Administration to pregnant women, lactating women, etc.
(1) HMG-CoA reductase inhibitors such as this drug can have serious effects on the fetus by reducing the biosynthesis of cholesterol, which is essential for fetal development, so they should not be administered to pregnant women or women who may be pregnant. Additionally, if you become pregnant while taking this medicine, stop taking it immediately and consider the overall risk to the fetus.
(2) Do not administer to women who are breastfeeding.

8. Administration to children, etc.
Safety and effectiveness in children, etc. have not been established. (No experience in using it)

9. Storage and handling precautions
(1) Store out of reach of children.
(2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container.

10. Pharmaceutical equivalence test information
A. As a result of measuring pitavastatin in the blood, one tablet each was administered orally once on an empty stomach to 47 healthy adults in a 2×2 crossover test of the test drug Pitovastatin 2 mg (pitavastatin calcium hydrate) [KyungDong Pharm Co., Ltd.] and the reference drug Livaro tablet 2 mg (pitavastatin calcium) [JW Pharmaceutical Co., Ltd.]. When Cmax) was log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, demonstrating biological equivalence.
*Table: Refer to manual

11. Other precautions
In an oral administration test in dogs (3 mg/kg/day or more for 3 months, 1 mg/kg/day or more for 12 months), cataracts were observed. Additionally, it did not appear in other animals (rats, monkeys).

5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3Pitrovan Tab. 2mgPrecautions for use2025.02.11PDF0053_201907395_Change order for precautions for use of Phytroban tablet 2 mg (draft).pdf
2Pitrovan Tab. 2mgPrecautions for use2021.01.15PDFPrecautions for use of Pitroban Tablet 2mg.pdf
1Pitrovan Tab. 2mgPrecautions for use2021.01.19HWPPitavastatin calcium single agent (tablet) change comparison table (1).hwp